Byrne Asset Management’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.5K | Buy |
+2,963
| New | +$38.5K | 0.03% | 286 |
|
|
2025
Q1 | – | Sell |
-1,520
| Closed | -$25.8K | – | 292 |
|
|
2024
Q4 | $25.8K | Sell |
1,520
-560
| -27% | -$9.5K | 0.02% | 257 |
|
|
2024
Q3 | $48.3K | Buy |
2,080
+240
| +13% | +$5.57K | 0.03% | 204 |
|
|
2024
Q2 | $45K | Sell |
1,840
-220
| -11% | -$5.38K | 0.03% | 210 |
|
|
2024
Q1 | $69.6K | Sell |
2,060
-270
| -12% | -$9.12K | 0.05% | 183 |
|
|
2023
Q4 | $76.3K | Sell |
2,330
-940
| -29% | -$30.8K | 0.06% | 165 |
|
|
2023
Q3 | $84K | Sell |
3,270
-230
| -7% | -$5.91K | 0.07% | 154 |
|
|
2023
Q2 | $100K | Sell |
3,500
-700
| -17% | -$20K | 0.07% | 193 |
|
|
2023
Q1 | $101K | Sell |
4,200
-2,315
| -36% | -$55.7K | 0.07% | 177 |
|
|
2022
Q4 | $110K | Buy |
6,515
+1,995
| +44% | +$33.8K | 0.08% | 171 |
|
|
2022
Q3 | $67K | Buy |
4,520
+370
| +9% | +$5.49K | 0.05% | 187 |
|
|
2022
Q2 | $74K | Buy |
4,150
+150
| +4% | +$2.68K | 0.05% | 163 |
|
|
2022
Q1 | $108K | Buy |
4,000
+910
| +29% | +$24.6K | 0.07% | 154 |
|
|
2021
Q4 | $114K | Buy |
+3,090
| New | +$114K | 0.07% | 153 |
|